| Metric | Value ($ M) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 25.3K | 5.2% | 6.6% |
| Total Income | 25.3K | 5.2% | 6.6% |
| Expenditure | 18.6K | 2.7% | 7.6% |
| PBT | 6.7K | 12.6% | 3.9% |
| Net Profit | 5.5K | 5.7% | 0.1% |
| OPM | — | ||
| NPM | 21.86% | 0.11pp | 1.46pp |
| EPS | 2.30 | 6.0% | 0.0% |
Johnson & Johnson Reports Q3 2026 Results, Raises 2026 Guidance
13 Oct 2026 · 1d ago, 5:51 pm
Summary
Johnson & Johnson announced strong third-quarter 2026 results, with reported sales reaching $25.4 billion, a 5.9% increase year-over-year, and operational sales growing by 6.0%. The company raised its full-year 2026 guidance, now expecting reported sales of $101.2 billion (7.4% growth) and adjusted EPS of $11.10 (2.9% growth). This performance reflects accelerating momentum in its focused portfolio, with notable advancements in innovation and strategic investments in high-growth areas.
Key Highlights
- 1
Johnson & Johnson reported third-quarter 2026 reported sales growth of 5.9% to $25.4 billion, with operational growth of 6.0%.
- 2
Adjusted EPS for the third quarter of 2026 was $2.59, reflecting the impact of special charges and acquisitions.
- 3
The company is increasing its full-year 2026 guidance, estimating reported sales of $101.2 billion, representing 7.4% growth at the midpoint.
- 4
Adjusted EPS guidance for the full year 2026 has been raised to $11.10 at the midpoint, a 2.9% increase.
- 5
Significant innovations were highlighted, including market authorization for OTTAVA, approval of IMAAVY, and priority review for RYBREVANT FASPRO.
- 6
Innovative Medicine operational sales grew 7.9% in the third quarter, driven by key products like TREMFYA and DARZALEX.
- 7
MedTech operational sales grew 2.5% in the third quarter, supported by electrophysiology products and Shockwave.
Management Comments
Joaquin Duato
Johnson & Johnson’s strong third-quarter performance and increased sequential growth reflect the accelerating momentum of our focused portfolio. In the third quarter, we advanced breakthroughs that will redefine care for patients, from delivering one of our most transformative MedTech innovations with OTTAVA to reporting positive Phase 3 results in multiple myeloma. This progress, together with strategic investments in high-growth areas, gives us clearer line of sight to double-digit growth by the end of the decade.
Informational and educational content only. Not investment advice.